DTP Oseltamivir Flashcards
Oseltamivir Drug class
Antiviral
Oseltamivir Pharmacology
a neuraminidase inhibitor that selectively inhibits
the influenza A and B viruses
Oseltamivir Metabolism
Absorbed in the GI tract and not affected by food, converted to active metabolite by esterase in the liver and excreted by kidneys
Oseltamivir Indications
Treatment of QAS operational staff with influenza like illnesses (ILI)
Oseltamivir Characteristics of ILI
Fever (> 38°C or have a good history of fever)
AND
Cough, sore throat, runny nose, congestion or GI upset.
Oseltamivir Contraindications
As per the QAS oseltamivir checklist
Oseltamivir Complications
Nil
Oseltamivir Side effects
Nausea and/or vomiting
Oseltamivir Presentation
Capsule, 75 mg (box of 10) oseltamivir (Tamiflu®)
Oseltamivir Onset (PO)
1 hour
Oseltamivir Duration (PO)
< 12 hours
Oseltamivir Half-life (elimination)
1 – 3 hours
Oseltamivir Schedule
• S4 (Restricted drugs).
Oseltamivir course and time frame
The patient is to be supplied with the full course of
oseltamivir.
Treatment should commence as soon as possible, but no later than 48 hours after the onset of fever.
Oseltamivir Administration authority and checklist
Oseltamivir is only to be administered
on direct authority of the QAS Medical Director
(e.g. medical circular announcement).
All staff members must meet the administration
criteria according to the ‘QAS oseltamivir
administration checklist’ prior to being
administered oseltamivir.
